71 studies found for:    "Kennedy disease"
Show Display Options
Rank Status Study
21 Recruiting Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Biomarker Analysis;   Drug: Enzalutamide;   Other: Pharmacological Study;   Drug: Taselisib
22 Not yet recruiting Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Paclitaxel
23 Recruiting Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Drug: Niclosamide;   Other: Pharmacological Study
24 Recruiting Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
Condition: Prostate Cancer
Intervention: Drug: Enzalutamide
25 Withdrawn Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
Condition: Breast Cancer Female
Interventions: Drug: oral microencapsulated diindolylmethane;   Other: laboratory biomarker analysis
26 Recruiting A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
Condition: Prostate Cancer
Interventions: Drug: Galeterone;   Drug: Enzalutamide
27 Recruiting A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Conditions: Advanced Breast Cancer;   Human Epidermal Growth Factor Receptor 2 (HER2);   HER2 Amplified
Interventions: Drug: enzalutamide;   Drug: trastuzumab
28 Completed Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Condition: Androgenetic Alopecia
Intervention: Drug: Finasteride
29 Completed Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy
Condition: Motor Neuron Disease
Interventions: Behavioral: A functional exercise program;   Behavioral: A stretching exercise program
30 Active, not recruiting A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: JNJ-56021927
31 Recruiting Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Condition: Breast Cancer
Intervention: Drug: Bicalutamide
32 Suspended A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasm
Intervention: Drug: EZN-4176
33 Recruiting Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Condition: Salivary Gland Cancer
Interventions: Drug: bicalutamide + triptorelin;   Drug: Cisplatin + Doxorubicin;   Drug: Carboplatin + Paclitaxel
34 Active, not recruiting Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
Condition: Prostate Cancer
Intervention: Procedure: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
35 Recruiting CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
Conditions: Metastatic Breast Adenocarcinoma;   Breast Cancer
Intervention: Drug: CR1447
36 Recruiting Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078
Condition: Cachexia
Interventions: Drug: GSK2881078;   Drug: Placebo;   Drug: Itraconazole
37 Recruiting Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Galunisertib;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
38 Completed Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Condition: Prostate Cancer
Intervention: Other: mutation analysis
39 Recruiting Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Conditions: Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis
40 Completed AR and ER Imaging in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Other: FDHT-PET scan;   Other: FES-PET scan;   Other: CT-scan;   Other: Bone scintigraphy;   Other: Tumor biopsy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years